Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Pfizer named Dr Chris Boshoff as CSO and president of R&D, effective 1st January 2025. Boshoff, previously Pfizer’s chief ...

The establishment of the ERAS protocols catalyses the changes in the IV treatment settings and highlights the need for a ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

While this subjective cognitive decline (SCD) linked to menopause tends to be transient, it can often occur at an age when ...

Hospitals should expand and speed up testing of people hospitalised with influenza to see if they are suffering from bird flu ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole Raleigh sat down with Pfizer’s ...

That is the conclusion of a report by the global Commission on Clinical Obesity – published in The Lancet Diabetes and ...